Affiliation:
1. Hospital Clínic de Barcelona
2. Inria Saclay - Île-de-France Research Centre
3. University of Barcelona
Abstract
Abstract
Background
Neuroimaging and fluid biomarkers are used in clinics to differentiate frontotemporal dementia (FTD) from Alzheimer’s disease (AD) and other neurodegenerative and non-neurodegenerative disorders. We implemented a machine learning (ML) algorithm that provides individual probabilistic scores for these patients based on magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) data.
Methods
We used a calibrated classifier with a Support Vector Machine with MRI data. We obtained group classifications and individual probabilities associated with group correspondence. We used the individual probabilities to address the clinical problem of confidence in the diagnosis. We investigated whether combining MRI and CSF levels of Neurofilament light (NfL) and 14-3-3 could improve the diagnosis confidence.
Results
215 AD patients (65 ± 10 years, 137 women), 103 FTD patients (64 ± 8 years, 49 women), and 173 healthy controls (CTR) (59 ± 15 years, 106 women) were studied. With MRI data only, we obtained accuracies of 88% in the AD vs. healthy controls (CTR) classification, 87% for FTD vs. CTR, 82% for AD vs. FTD, and 80% when differentiating the three groups. A total of 74% of FTD and 73% of AD participants have a high (≥ 0.8) probability of accurate diagnosis in the FTD vs. AD comparison. Adding CSF-NfL and 14-3-3 levels slightly improved the accuracy and the number of patients in the high diagnosis confidence group.
Conclusion
We propose a ML algorithm that provides individual diagnostic probabilities, and we validate it using MRI and/or CSF data. Our solution holds promise towards clinical applications as support to clinical findings or in settings with limited access to expert diagnoses.
Publisher
Research Square Platform LLC
Reference60 articles.
1. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease;Albert MS;Alzheimer’s and Dementia,2011
2. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease;McKhann GM;Alzheimer’s and Dementia,2011
3. CSF sAPPβ, YKL-40, and neurofilament light in frontotemporal lobar degeneration;Alcolea D;Neurology,2017
4. Antonell A, Tort-Merino A, Ríos J, Balasa M, Borrego-Écija S, Auge JM, et al. Synaptic, axonal damage and inflammatory cerebrospinal fluid biomarkers in neurodegenerative dementias. Alzheimer’s & Dementia [Internet]. 2019 Oct 24 [cited 2022 Dec 7]; Available from: https://www.sciencedirect.com/science/article/pii/S1552526019353695
5. Dysregulation of 14-3-3 proteins in neurodegenerative diseases with Lewy body or Alzheimer pathology;McFerrin MB;Ann Clin Transl Neurol,2017